Compare Autodesk Inc (ADSK) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.

The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.